Table 2.
ALL: patient, disease, and transplantation characteristics
| Variable | Training cohort n (%) | Validation cohort n (%) | P |
|---|---|---|---|
| Patients, n | 673 | 672 | |
| Age at transplantation, y* | .81 | ||
| <2 y | 35 (5) | 33 (5) | |
| ≥2 y | 638 (95) | 639 (95) | |
| Sex | .22 | ||
| Male | 407 (60) | 428 (64) | |
| Female | 266 (40) | 244 (36) | |
| Hematopoietic comorbidity index score | .61 | ||
| ≤2 | 561 (83) | 560 (83) | |
| ≥3 | 112 (17) | 111 (17) | |
| Not reported | 0 | 1 (<1) | |
| Performance score | .93 | ||
| 90-100 | 560 (83) | 556 (83) | |
| ≤80 | 102 (15) | 106 (16) | |
| Not reported | 11 (2) | 10 (1) | |
| Cytomegalovirus serostatus | .59 | ||
| Negative | 247 (37) | 265 (39) | |
| Positive | 420 (62) | 401 (60) | |
| Not reported | 6 (1) | 6 (1) | |
| Cytogenetic risk† | .21 | ||
| Intermediate | 394 (59) | 376 (56) | |
| Poor | 235 (35) | 262 (39) | |
| Not reported | 44 (7) | 34 (5) | |
| Disease status | .61 | ||
| 1st complete remission MRD+ | 89 (13) | 82 (12) | |
| 1st complete remission MRD− | 173 (26) | 165 (25) | |
| 1st complete remission | 8 (1) | 13 (2) | |
| 2nd complete remission MRD+ | 71 (11) | 85 (13) | |
| 3rd complete remission MRD+ | 20 (3) | 13 (2) | |
| 2nd complete remission MRD− | 215 (32) | 220 (33) | |
| 3rd complete remission MRD− | 44 (7) | 50 (7) | |
| ≥2nd complete remission | 21 (3) | 23 (3) | |
| Not in remission | 32 (5) | 21 (3) | |
| Donor | .83 | ||
| HLA-matched sibling | 123 (18) | 132 (20) | |
| HLA-mismatched relative | 61 (9) | 56 (8) | |
| HLA-matched unrelated | 168 (25) | 167 (25) | |
| 1-locus mismatched unrelated | 64 (10) | 69 (10) | |
| 6-8/8 HLA-matched cord blood | 145 (22) | 152 (23) | |
| ≤5/8 HLA-matched cord blood | 112 (17) | 96 (14) | |
| Conditioning regimen | .78 | ||
| TBI/cyclophosphamide | 251 (37) | 227 (34) | |
| TBI/cyclophosphamide/fludarabine | 158 (23) | 176 (26) | |
| TBI/cyclophosphamide+other | 166 (25) | 164 (24) | |
| TBI+other | 58 (9) | 68 (10) | |
| Busulfan/cyclophosphamide | 13 (2) | 13 (2) | |
| Busulfan/melphalan | 10 (1) | 8 (1) | |
| Fludarabine/busulfan/thiotepa | 17 (3) | 16 (2) | |
| GVHD prophylaxis | .15 | ||
| Ex vivo T-cell depletion/CD34 selection | 42 (6) | 33 (5) | |
| Post-transplantation CY, with or without other(s) | 21 (3) | 36 (5) | |
| Calcineurin inhibitor+mycophenolate | 247 (37) | 238 (40) | |
| Calcineurin inhibitor+methotrexate | 304 (45) | 306 (46) | |
| Calcineurin inhibitor, with or without other | 46 (7) | 47 (8) | |
| Other | 13 (2) | 12 (2) | |
| Transplantation period | .52 | ||
| 2008-2012 | 196 (29) | 185 (28) | |
| 2013-2017 | 477 (71) | 487 (72) |
Data are the number of patients (percentage of subgroup), unless stated otherwise.
CY, cyclophosphamide.
*
Age distribution. Training cohort: n = 35 (5%) aged <2 y, n = 190 (28%) aged 2-6 y, n = 201 (30%) aged 7-11 y, and n = 247 (37%) aged 12-18 y. Validation cohort: n = 33 (4%) aged <2 y, n = 180 (27%) aged 2-6 y, n = 228 (34%) aged 7-11 y, and n = 231 (34%) aged 12-18 y.
†
Cytogenetic risk: poor ((t9;22), iAMP21, abnormal 17p, loss of 13q, and 11q23 [infant]); intermediate (all others).